PKM and cancer: As shown in Figure 3(e) and Figure S5, compared to the normal tissues, promoter methylation levels of PKM2 were significantly downregulated in the majority of cancers (except PCPG), such as BLCA, BRCA, CHOL, HNSC, KIRC, KIRP, PAAD, TGCT, PRAD, THCA, and UCEC.